Scientific Publications, Posters & Presentations

Publications
Publications that have resulted from Ardea Biosciences’ proprietary research programs or through research collaborations with other biotechnology or pharmaceutical companies will be posted below once available. The links for the articles go to subscription-based sites and may require a fee to view the article.

Presentations

	48th Annual ICAAC/IDSA 46th Annual Meeting
	RDEA806, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment Naïve HIV Patients
	2008 ACR/ARHP Annual Scientific Meeting
	MEK Inhibitor RDEA119 Suppresses Inflammatory Cytokine Production Induced by Monosodium Urate Crystals
	XVII International AIDS Conference
	Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients
	Digestive Disease Week 2008
	RDEA119, A Potent and Highly Selective MEK Inhibitor Ameliorates Murine Colitis

 

Posters

	RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients
	Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species
	Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of RDEA594, A Novel, Uricosuric Agent, In Healthy Volunteers
	RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important Renal Transporters, OAT1 and OAT3
	Selective MEK1/2 Inhibitors RDEA436 and RDEA119 Exhibit Anti-Inflammatory Efficacy in Mono and Combination Therapy with Methotrexate in Pristane-Induced Arthritis in Rats
	The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents
	In Vitro Resistance Selection Study and Favorable PK Properties of RDEA427, a New NNRTI
	RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806
	The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial
	Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTI’s
	RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer
	RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice
	Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor
	Biosynthesis of Oxidative and Conjugated Metabolites of VRX-480773 and Identification of their Structures by LC-MS/MS and NMR
	Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, a Novel Prodrug for the Potential Treatment of Hyperuricemia
	Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Pro-drug, RDEA806
	RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis
	RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties
	RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies
	A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses
	RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses
	An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins
	RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer
	The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials
	RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance
	Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers
	RDEA806, A Potent Non-Nucleoside Reverse Transcriptase Inhibitor with Less Potential for Drug-Drug Interactions